ACST - Acasti Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Acasti Pharma Inc.

545, Promenade du Centropolis
Suite 100
Laval, QC H7T 0A3
Canada
450-687-2262
http://www.acastipharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Ms. Janelle D' AlvisePres, CEO, Corp. Sec. & DirectorN/AN/AN/A
Dr. Pierre LemieuxCo-Founder and COO & Chief Scientific OfficerN/AN/AN/A
Mr. Jean-François BoilyVP of Fin.N/AN/AN/A
Mr. Brian James GrochChief Commercial OfficerN/AN/A1967
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Corporate Governance

Acasti Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.